225 related articles for article (PubMed ID: 29601137)
21. NK/T Cell Lymphoma: Updates in Therapy.
Suzuki R
Curr Hematol Malig Rep; 2018 Feb; 13(1):7-12. PubMed ID: 29368155
[TBL] [Abstract][Full Text] [Related]
22. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
23. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
[TBL] [Abstract][Full Text] [Related]
24. Impact of dexamethasone, etoposide, ifosfamide and carboplatin as concurrent chemoradiotherapy agents for nasal natural killer/T-cell lymphoma.
Hatayama Y; Aoki M; Kawaguchi H; Narita Y; Hirose K; Sato M; Takai Y
Mol Clin Oncol; 2013 Jul; 1(4):680-684. PubMed ID: 24649228
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of localized nasal NK/T-cell lymphoma].
Yamaguchi M
Rinsho Ketsueki; 2008 Aug; 49(8):553-8. PubMed ID: 18800601
[No Abstract] [Full Text] [Related]
26. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
28. SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type.
Wei L; Wang L; Cong J; Yang L; Ye J; Li X; Yao N; Yang J; Wang J
Leuk Res; 2020 Sep; 96():106422. PubMed ID: 32721642
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type.
Tian S; Li R; Wang T; Wang S; Tao R; Hu X; Ding H
Cancer Med; 2019 Jul; 8(7):3349-3358. PubMed ID: 31050212
[TBL] [Abstract][Full Text] [Related]
30. Current treatment approaches for NK/T-cell lymphoma.
Yamaguchi M; Miyazaki K
J Clin Exp Hematop; 2017 Dec; 57(3):98-108. PubMed ID: 28679966
[TBL] [Abstract][Full Text] [Related]
31. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
32. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
[TBL] [Abstract][Full Text] [Related]
33. Extranodal NK/T-cell lymphoma: Updates in biology and management strategies.
Yamaguchi M; Oguchi M; Suzuki R
Best Pract Res Clin Haematol; 2018 Sep; 31(3):315-321. PubMed ID: 30213402
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
35. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Motomura K; Natsume A; Fujii M; Ito M; Momota H; Wakabayashi T
Leuk Lymphoma; 2011 Nov; 52(11):2069-75. PubMed ID: 21745167
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
Suzuki R
Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
[TBL] [Abstract][Full Text] [Related]
38. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
39. [Extranodal NK/T-cell lymphoma].
Suzuki R
Nihon Rinsho; 2014 Mar; 72(3):524-30. PubMed ID: 24724414
[TBL] [Abstract][Full Text] [Related]
40. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]